Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain

Last updated: February 7, 2022
Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Overall Status: Completed

Phase

2

Condition

Pain

Pain (Pediatric)

Oral Facial Pain

Treatment

N/A

Clinical Study ID

NCT03317613
2017-0304
2017-002476-11
  • Ages > 18
  • All Genders

Study Summary

In the oncology area, neuropathic pains are relatively frequent and can be induced by surgery, radiotherapy, or chemotherapy. In usual practice, some units are using qutenza in order to reduce neuropathic pain even though using of this patch for a population of cancer patients has never been demonstrated so far in a prospective study. The present prospective study proposes to evaluate the qutenza efficacy in peripheric neuropathic pain in cancer patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient with at least 18 years old;
  • Patient presenting neuropathic pain secondary to an anti-cancerous treatment;
  • Patient presenting a DN4 (Neuropathic Pain in Four Questions) score superior or equalto 4 out of 10
  • Patient presenting a skin without lesion at the painful area
  • Informed consent form signed;
  • Patient affiliated to a social security scheme.

Exclusion

Exclusion Criteria:

  • Hypersensitivity known to capsaicin;
  • Instable or uncontrolled hypertension;
  • Painful area localised next to eyes;
  • Pregnant or breastfeeding woman;
  • Protected people.

Study Design

Total Participants: 84
Study Start date:
November 09, 2017
Estimated Completion Date:
December 20, 2021

Study Description

Drugs for neuropathic pains are generally represented by antidepressants, anti-epileptics, opioids, lidocaine patch. However, these drugs can frequently be insufficient, and/or can lead to side effects. Qutenza (8% capsaicin patch) presents an interesting alternative.

Qutenza efficacy has been shown in five principal studies conducted on 1988 adults affected by moderate or severe neuropathic pains. All patients presented Postherpetic neuralgia, or HIV associated therapy, or painful diabetic peripheric neuropathies. These studies led to qutenza approbation in Europe and in States in 2009.

In oncology, neuropathic pains are relatively frequent and can be induced by the three big actors of the anti-cancerous therapeutic arsenal (surgery, radiotherapy, chemotherapy). In usual practice, some units are usually using qutenza, but the use of this patch for this kind of patients has not been shown in a prospective study. Advantages of this treatment are numerous, and results presented in other therapeutic area are encouraging its use in oncology.

The present prospective study proposes to evaluate the qutenza efficacy in peripheric neuropathic pain in cancer patients.

Connect with a study center

  • Centre Jean Perrin

    Clermont-Ferrand, 63000
    France

    Site Not Available

  • Centre Hospitalier Emile Roux

    Le Puy-en-Velay, 43000
    France

    Site Not Available

  • Institut de Cancérologie Lucien Neuwirth

    Saint-Priest-en-Jarez, 42271
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.